First Trust NYSE Arca Biotechnology Index Fund (FBT)

NYSEARCA: FBT · IEX Real-Time Price · USD
-0.74 (-0.50%)
Sep 22, 2023, 4:00 PM EDT - Market closed
Assets $1.36B
Expense Ratio 0.56%
PE Ratio 17.02
Shares Out n/a
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
Payout Ratio n/a
1-Year Return +9.75%
Volume 13,491
Open 146.69
Previous Close 146.67
Day's Range 145.92 - 147.21
52-Week Low 128.51
52-Week High 166.00
Beta n/a
Holdings 31
Inception Date Jun 19, 2006

About FBT

Fund Home Page

The First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund that is based on the NYSE Arca Biotechnology index. The fund tracks an equal-weighted index of US biotechnology stocks. FBT was launched on Jun 19, 2006 and is issued by First Trust.

Asset Class Equity
Category Health
Region North America
Stock Exchange NYSEARCA
Ticker Symbol FBT
Index Tracked NYSE Arca Biotechnology Index

Top 10 Holdings

38.31% of assets
Name Symbol Weight
Amgen Inc. AMGN 4.11%
Neurocrine Biosciences, Inc. NBIX 4.11%
Sarepta Therapeutics, Inc. SRPT 4.05%
Regeneron Pharmaceuticals, Inc. REGN 4.02%
Exelixis, Inc. EXEL 3.93%
Seagen Inc. SGEN 3.80%
Ionis Pharmaceuticals, Inc. IONS 3.75%
BioMarin Pharmaceutical Inc. BMRN 3.53%
BioNTech SE BNTX 3.51%
Vertex Pharmaceuticals Incorporated VRTX 3.50%
View More Holdings


Ex-Dividend Amount Pay Date
2021-12-30 $2.214 2022-01-10
2015-09-23 $0.0197 2015-09-30
2015-06-24 $0.0649 2015-06-30
2015-03-25 $0.0476 2015-03-31
2014-12-23 $0.0524 2014-12-31
Full Dividend History


Here are the top-performing ETFs in first half of 2023 as crypto-related funds soar

Hello! This week's ETF Wrap looks at top performers in the first half of 2023, as well as flows, as stocks rally and crypto-related funds jump so far this year.

3 months ago - Market Watch

Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?

Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators ...

Other symbols: BBHPBE
2 years ago - ETF Trends

5 Top ETFs With Exposure To Biogen

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical dec...

2 years ago - Benzinga

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...

Other symbols: BBHPBE
3 years ago - Benzinga

Can't Get Enough Biotech Exposure in Your Portfolio?

As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds...

Other symbols: ARKGBBHXBI
3 years ago - ETF Trends

Biotech ETFs at multi-week highs, extending winning streak

Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...

Other symbols: BBHIBBXBI
3 years ago - Market Watch

Biotech ETFs at two-week highs on upbeat vaccine news

Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biote...

Other symbols: ARKGSBIO
3 years ago - Market Watch

Encouraging Election Year History for this Biotech ETF

Healthcare is one of the most politically sensitive sectors and that sensitivity is on full display in recent weeks with biotechnology ETFs, including the First Trust NYSE Arca Biotechnology Index Fun...

3 years ago - ETF Trends

Election History Says Buy Biotech Dip

Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ign...

3 years ago - Benzinga

Post-Pandemic Stars Could Align For This Biotech ETF

These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.

3 years ago - Benzinga

Biotech ETFs Still Promising Despite Hydroxychloroquine Trial

In the continuing quest to find a vaccine for the coronavirus, the World Health Organization announced Wednesday it is dropping hydroxychloroquine, the malaria drug backed by President Trump, who clai...

Other symbols: BBH
3 years ago - ETF Trends

There’s Still Plenty of Opportunity for Biotech Post-Coronavirus

While the Coronavirus pandemic continues dominating healthcare sector headlines, investors shouldn’t fret that biotechnology ETFs will be left vulnerable when the virus is finally vanquished. That’s g...

3 years ago - ETF Trends

ACADIA Pharmaceuticals Help Lift Biotech ETFs

While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA Pharmaceuticals (NasdaqGS:...

Other symbols: BBPIBBSBIO
4 years ago - ETF Trends

Biotech stocks fall after Trump promises executive order drug prices

CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.

4 years ago - CNBC Television

Is now the time to buy Nike? What about biotech? #AskHalftime

The "Halftime Report" traders take viewer questions on Nike and biotech.

Other symbols: IBBNKEXBI
5 years ago - CNBC Television